GRIN3B
Glutamate receptor ionotropic, NMDA 3B
As of the edition of 20 October 2026, GRIN3B (glutamate receptor ionotropic, NMDA 3B, UniProt O60391) has 17 drugs tested at it and 24 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O60391
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Mental health; Nervous system; Cancer; Chemically induced; Injuries; Lungs and airways; Infections; Inherited and neonatal
- Registered trials of its drugs
- 1,356
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ketamine | Marketed | Phase 4 | none listed |
| Esketamine | Marketed | Phase 4 | Ends 2028 |
| Memantine | Marketed | Phase 4 | none listed |
| Amantadine | Marketed | Phase 4 | none listed |
| Acamprosate | Marketed | Phase 4 | none listed |
| Rapastinel | Stopped | Phase 3 | none listed |
| Neramexane | Stopped | Phase 3 | none listed |
| Lanicemine | Went quiet | Phase 2 | none listed |
| AV-101 | Stopped | Phase 3 | none listed |
| Apimostinel | Active | Phase 2 | none listed |
| Indantadol | Stopped | Phase 2 | none listed |
| CLE-100 | Status not established | Phase 2 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 24 |
| Total on the list | 24 |